These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 3016942

  • 41. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
    Zahavi M, Zahavi J, Kakkar VV.
    Thromb Haemost; 1984 Oct 31; 52(2):205-9. PubMed ID: 6098048
    [Abstract] [Full Text] [Related]

  • 42. Effects of dilazep on cytoplasmic calcium ion concentrations and arachidonic acid metabolism in activated human platelets.
    Okuma M, Kanaji K, Sensaki S, Uchino H.
    Arzneimittelforschung; 1989 Mar 31; 39(3):372-5. PubMed ID: 2502990
    [Abstract] [Full Text] [Related]

  • 43. Transport and metabolism of adenosine in human erythrocytes: effect of transport inhibitors and regulation by phosphate.
    Plagemann PG.
    J Cell Physiol; 1986 Sep 31; 128(3):491-500. PubMed ID: 3488996
    [Abstract] [Full Text] [Related]

  • 44. Inhibition of human platelet aggregation by dihydropyrano- and dihydrofuranocoumarins, a new class of cAMP-phosphodiesterase inhibitors.
    Thastrup O, Knudsen JB, Lemmich J, Winther K.
    Biochem Pharmacol; 1985 Jun 15; 34(12):2137-40. PubMed ID: 2988567
    [Abstract] [Full Text] [Related]

  • 45. Platelet-activating factor (PAF)-induced platelet aggregation. Modulation by plasma adenosine and methylxanthines.
    Agarwal KC, Clarke E, Rounds S, Parks RE, Huzoor-Akbar.
    Biochem Pharmacol; 1994 Nov 16; 48(10):1909-16. PubMed ID: 7986202
    [Abstract] [Full Text] [Related]

  • 46. Calcium entry blocking activity of dilazep in dog coronary artery.
    Nakagawa Y, Gudenzi M, Mustafa SJ.
    Pharmacology; 1986 Nov 16; 33(3):148-56. PubMed ID: 3018802
    [Abstract] [Full Text] [Related]

  • 47. Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo.
    Bullough DA, Zhang C, Montag A, Mullane KM, Young MA.
    J Clin Invest; 1994 Oct 16; 94(4):1524-32. PubMed ID: 7929829
    [Abstract] [Full Text] [Related]

  • 48. Inhibition of adenylate cyclase attenuates adenosine receptor-mediated relaxation in coronary artery.
    Sabouni MH, Cushing DJ, Makujina SR, Mustafa SJ.
    J Pharmacol Exp Ther; 1991 Nov 16; 259(2):508-12. PubMed ID: 1658301
    [Abstract] [Full Text] [Related]

  • 49. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets.
    Simpson AW, Reeves ML, Rink TJ.
    Biochem Pharmacol; 1988 Jun 15; 37(12):2315-20. PubMed ID: 2455518
    [Abstract] [Full Text] [Related]

  • 50. Nucleoside transport in rat cerebral-cortical synaptosomes. Evidence for two types of nucleoside transporters.
    Lee CW, Jarvis SM.
    Biochem J; 1988 Jan 15; 249(2):557-64. PubMed ID: 3342028
    [Abstract] [Full Text] [Related]

  • 51. Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.
    Sudo T, Ito H, Ozeki Y, Kimura Y.
    Br J Pharmacol; 2001 Aug 15; 133(8):1396-404. PubMed ID: 11498527
    [Abstract] [Full Text] [Related]

  • 52. 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.
    Martinez GR, Walker KA, Hirschfeld DR, Bruno JJ, Yang DS, Maloney PJ.
    J Med Chem; 1992 Feb 21; 35(4):620-8. PubMed ID: 1311763
    [Abstract] [Full Text] [Related]

  • 53. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.
    Ruppert D, Weithmann KU.
    Life Sci; 1982 Nov 08; 31(19):2037-43. PubMed ID: 6294426
    [Abstract] [Full Text] [Related]

  • 54. Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change.
    Jensen BO, Kleppe R, Kopperud R, Nygaard G, Døskeland SO, Holmsen H, Selheim F.
    Platelets; 2011 Nov 08; 22(1):8-19. PubMed ID: 20958117
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
    Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, Hidaka H.
    Biochem Pharmacol; 2000 Feb 15; 59(4):347-56. PubMed ID: 10644042
    [Abstract] [Full Text] [Related]

  • 59. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
    Liao CH, Tzeng CC, Teng CM.
    Eur J Pharmacol; 1998 May 15; 349(1):107-14. PubMed ID: 9669503
    [Abstract] [Full Text] [Related]

  • 60. The antilipolytic effect of endogenous and exogenous adenosine in canine adipose tissue in situ.
    Sollevi A, Fredholm BB.
    Acta Physiol Scand; 1981 Sep 15; 113(1):53-60. PubMed ID: 7315438
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.